Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena J Edelman

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Plos Computational Biology|February 20, 2008
Modeling cancer progression via pathway dependenciesElena J Edelman, Justin Guinney, Jen-Tsan Chi, et al.
Genes & Development|November 11, 2010
A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migrationGromoslaw A Smolen, Jianmin Zhang, Matthew J Zubrowski, et al.
Nucleic Acids Research|November 28, 2012
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cellsWanjuan Yang, Jorge Soares, Patricia Greninger, et al.
Cancer Discovery|October 29, 2013
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1Anthony C Faber, Erin M Coffee, Carlotta Costa, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 5, 2015
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancerAnthony C Faber, Anna F Farago, Carlotta Costa, et al.
Nature|March 31, 2012
Systematic identification of genomic markers of drug sensitivity in cancer cellsMathew J Garnett, Elena J Edelman, Sonja J Heidorn, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Plos Computational Biology|February 20, 2008
Modeling cancer progression via pathway dependenciesElena J Edelman, Justin Guinney, Jen-Tsan Chi, et al.
Genes & Development|November 11, 2010
A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migrationGromoslaw A Smolen, Jianmin Zhang, Matthew J Zubrowski, et al.
Nucleic Acids Research|November 28, 2012
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cellsWanjuan Yang, Jorge Soares, Patricia Greninger, et al.
Cancer Discovery|October 29, 2013
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1Anthony C Faber, Erin M Coffee, Carlotta Costa, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 5, 2015
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancerAnthony C Faber, Anna F Farago, Carlotta Costa, et al.
Nature|March 31, 2012
Systematic identification of genomic markers of drug sensitivity in cancer cellsMathew J Garnett, Elena J Edelman, Sonja J Heidorn, et al.
Pageof 1